BofA Securities Reiterates Neutral Rating on Arcus Biosciences (RCUS)
Tweet Send to a Friend
BofA Securities analyst Jason Zemansky reiterated a Neutral rating and $22.00 price target on Arcus Biosciences (NYSE: RCUS).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
